Group items tagged

The Pharmaceutical Services Negotiating Committee (PSNC) has expressed its concerns over sustained pressures on medicines supply that are having a very serious impact on community pharmacy teams and their patients. It has asked contractors and their teams to continue using its regular reporting tools to help them demonstrate the scale of the problems to the Department of Health and Social Care (DHSC) and to support escalations as needed. The committee said: "The sustained increases in price concessions that we have seen so far in 2022 - with more than 100 concessions being granted in some months - show no signs of abating, and we know that many pharmacies now find themselves in a critical situation trying to source medicines in timely manner and facing significant financial risk due to greater uncertainty around expected reimbursement prices for a large number of medicines." "We know that some concessions being imposed by the Department do not match contractors' experience on the ground, and we would ask all contractors to continue reporting pricing issues to us on a regular basis to support our representations: Report product over Drug Tariff price."

WBA, Boots parent company revealed the results for its fourth quarter of the financial year, showing three months to August 2023. The reports published on 12 October show the loss of at least $1bn following a net loss of $3.1bn on an annual basis. This marks a decrease compared to a profit of $4.3bn in the previous financial year. The loss was attributed in part to a $5.5 billion after-tax charge related to opioid claims and litigation during the period, as well as the comparison against a $2.5 billion after-tax gain from the company's investments in Village MD and Shields Health Solutions in the same period last year. Ginger Graham, WBA's Interim Chief Executive spoke about the company's performance and its dedication to their customers and patients.

Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England regarding medicine pricing issues reported by pharmacy owners (its members). A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month. Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price. The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients. The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery. The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19. People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.

The National Institute of Health and Care Excellence has recommended that surgeons working in hospitals with limited or no access to a radiopharmacy department could now use Magtrace and Sentimag as an option to locate sentinel lymph nodes in people with breast cancer. The recommendation in draft NICE medical technology guidance could see a change in NHS standard care for the first time in years. The technology could also mitigate the reliance on radioactive isotope tracers shipped in from outside Great Britain. The magnetic liquid tracer - Magtrace - is a non-radioactive dark brown liquid. It is both a magnetic marker and a visual dye. The Magtrace is injected into the tissue around a tumour. The particles are then absorbed into the lymphatic system, following the route that cancer cells are most likely to take when they spread from the primary tumour and become trapped in sentinel lymph nodes. The Sentimag probe moves over the skin emitting sounds of different pitches as it passes over the Magtrace tracer, in a similar way to a metal detector locating metal in the ground. The nodes often appear dark brown or black in colour, which also helps with identification.

Community pharmacy workforce is in a fragile condition and faced a shortfall of 3,000 pharmacists in England over a period of five years, a recent research conducted by the Company Chemists' Association (CCA) has revealed. It noted that over the last five years, the net growth of community pharmacists in England a year stood at 733. This is much lower than the required average growth of 1,025, based on data reported by the Health Education England workforce survey from 2021. Acknowledging the discrepancies in the data calculation, the paper published by the association has used "the best available data" to highlight recent changes to the community pharmacy workforce in England. The report noted that despite an increase in the number of pharmacists, many contractors reported an increase in pharmacist vacancies. They also reported a significant increase in locum hourly pay rates, indicating demand exceeds supply.

Community pharmacies in Cornwall have delivered more than 8000 face-to-face consultations over last 12 months. Walk In Consultation Service (WICS) began 12 months ago when pharmacies in Cornwall started offering face-to-face consultations for a wide range of minor ailments, and NHS treatment as required - the first service of its kind in England. Cornwall & Isles of Scilly Scilly Local Pharmaceutical Committee (LPC) Chief Officer Nick Kaye joined Operations Manager Drew Creek in Parliament recently by invite of Steve Double MP, St Austell and Newquay to meet with Minister for Health Neil O'Brien MP to present the service to them and Senior Civil Servants from DHSC and NHSE with a view to rolling this service out nationally. The data from these consultations show that over 6000 GP appointments were averted as a result of the service being available. After each consultation a record was sent to the patient's GP for information.

The Competition and Markets Authority (CMA) has launched an investigation following 'rocketing prices of antibiotics in the wake of Strep A cases', Sky News reported on Wednesday (December 14). On Monday, the Department of Health issued a medicine supply notification for antibiotics for the treatment of Strep A. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies. Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days" said DHSC. Sky quoted a spokesperson for the CMA as saying: "People have got real concerns about the price of antibiotics used to treat Strep A, and we want companies to be clear about their obligations under the law.

The General Pharmaceutical Council (GPhC) has promoted Louise Edwards to the position of Chief Strategy Officer and Deputy Registrar. Louise is currently the Director of Regulation and Digital Transformation at the Electoral Commission, responsible for the organisation's regulatory work and digital, data, technology and facilities infrastructure. This includes funding and spending at elections and referendums, registering political parties, enforcement work, and data and information management. Louise will take over Mark Voce, the GPhC's current Chief Strategy Officer and Deputy Registrar, who is retiring early in July 2024. Louise said: "Pharmacy services are at the heart of health care for many people. Having effective regulation and standards in place can transform and give confidence in the quality of care that people receive.

Majority of the pharmacies are facing aggression from patients due to the medicine supply chain issue, a PSNC survey has revealed. The Pharmacy Pressures Survey by the trade body has seen nearly 83 per cent of pharmacies reporting a significant increase in medicine supply issues in the past year, leading to extra work and additional stress for staff. The survey of over 5,000 pharmacy premises and 1,000 pharmacy team members in England took place in early 2022. Two-thirds of respondents said that medicines supply chain issues are a daily occurrence, with 97 per cent reporting that this led to frustration from patients. "The results of PSNC's Pressures Survey make distressing reading for anybody in the sector - they tell a story of teams under immense pressures, and of businesses at crisis point," said Janet Morrison, PSNC chief executive.

Tough times for community pharmacies in England are far from over as the industry continues to grapple with major gaps in the workforce. Even though the latest figures released by the Health Education England (HEE) Community Pharmacy Workforce Survey 2021 showed doubling of pharmacist vacancy rate in England to 8 per cent between 2017 and 2021, it flagged the contractors' difficulty level in filling up these positions. The survey report showcased changes in the size and make-up of the community pharmacy workforce since the last survey conducted in 2017. It revealed that 56 per cent of pharmacy contractors reported high difficulty level in recruiting pharmacists, up from 21 per cent in the earlier survey. Moreover, a greater proportion - 60 per cent of contractors found filling up the pharmacy technician role 'fairly' or 'very' difficult. Other roles in the sector considered difficult to fill included accuracy checkers and trained dispensing assistants, both at 58 per cent.

Pharmacy Business will be hosting their annual awards event in the pharmacy calendar with a glittering ceremony to celebrate the very best of community pharmacy. The 23rd edition of the Pharmacy Business Awards will be on Wednesday 4 October 2023 in central London. The awards attract the biggest names in pharmacy, with heads of pharmacy organisations, CEOs of leading manufacturers and wholesalers, health officials and government ministers in attendance. We look forward to bringing together the shining lights of community pharmacy, who show the nation the unique services they continue to provide. REASONS TO ATTEND Understand what the ambitions of the NHS and PSNC are for the future of community pharmacy Understand why its important to develop a wider range of health services Learn how others are achieving this and what the benefits can be Learn what the benefits of embracing technological innovations are Hear what others are doing and what the benefits are to their business Network with and learn from your peers in community pharmacy WHO SHOULD ATTEND? Pharmacy owners Pharmacy managers Other pharmacy stakeholders Exciting news! Pharmacy Business Awards 2023 are just around the corner!

Pharmacy bodies and MPs discussed on support needed to unlock the "full potential" of community pharmacy at the All Pharmacy Party Group (APPG)'s general meeting held in Westminster on Tuesday (01 November). The attendees of the meeting were Janet Morrison OBE, Chief Executive of Pharmaceutical Services Negotiating Committee; Malcolm Harrison, Chief Executive of The Company Chemists' Association; Thorrun Govind, Chair of the Royal Pharmaceutical Society; Sanjeev Panesar, National Pharmacy Association Board Member, and Pharmacist Superintendent and Owner of the Pan Pharmacy Group; and Sandeep Dhami, Association of Independent Multiple Pharmacies member and superintendent at MW Phillips Chemist At the session, 18 parliamentarians were briefed on the myriad of ways pharmacies contribute to the health of the nation. The panel of experts also highlighted that pharmacists are 'running out of fuel' with the growing challenges such as flat funding, workforce shortages and the cost-of-living crisis impacting pharmacies' ability to deliver vital services.

The Pharmacists' Defence Association (PDA) has welcomed the government's defeat in the House of Lords on the Strikes (Minimum Service Levels) Bill. It believes that the proposed Bill, if enacted, would allow the government to dictate minimum levels of service during times of industrial action, enabling employers to name specific employees that they require in work. Those employees could then face losing their jobs if they failed to turn up to work on that day. Trade unions could also be fined if they did not force those named individuals to go to work. PDA director, Paul Day said, "This Bill should be of real concern to pharmacists and other health professionals. The idea of their employer being able to effectively conscript them to work or face the sack does not feel like a positive employment relations environment." The House of Lords has voted for key amendments to the Bill to prevent unions from being required to force workers to comply. This also prevents workers from being forced to work or face the sack and allows for greater consultation and Parliamentary scrutiny on the proposals which the Westminster government is trying to implement. The House of Commons will now be required to vote on the amendments over the next few weeks. Whilst the House of Lords amendments are likely to be defeated, it shows the degree of opposition there is to this Bill.

England is set to reopen temporary field hospitals to contain a possible overspill of inpatients due to a surge in coronavirus cases, the national health service said Thursday. Fuelled by the highly contagious Omicron variant, daily cases have ballooned, standing at more than 183,000 on Wednesday. NHS England said it would start building the structures in the grounds of eight hospitals in cities including London, Bristol and Leeds from this week, with each designed to house around 100 extra patients. "Given the high level of Covid-19 infections and increasing hospital admissions, the NHS is now on a war footing," National medical director Stephen Powis said. The extra beds are designed for patients who are recovering from illnesses, including those who no longer have Covid, to free up space and staff to treat large numbers of virus cases.

Health and Social Care Secretary Sajid Javid and Madelaine McTernan, head of the HRT supply taskforce, continue to take urgent action to resolve the shortage of HRT medicines by meeting the drug manufacturers and representatives from community pharmacies on Thursday (May 5). In the meeting, manufacturers outlined the steps they're taking to boost supply, and pharmacists shared their experiences on the frontline, as well as sharing their thoughts on wider solutions including improved communications. Aspen Pharmacare, Besins-Healthcare, Gedeon Richter, Novartis, Novo Nordisk, Orion, Pfizer, Theramex, Viatris, and representatives from community pharmacies were part of the meeting. As the government confirmed its intention to work with industry to do what is necessary to fix the HRT supply issue, Javis said he wanted to understand the issues facing suppliers and what can be done to address them. "We will leave no stone unturned in our national mission to boost supply of HRT. Along with appointing Madelaine McTernan as head of the HRT supply taskforce to implement lessons learned from the pandemic, and ensuring prescriptions are issued in shorter cycles for now, we are working collectively with the sector to urgently resolve this issue," he commented. The Association of Independent Multiple Pharmacies (AIMp) said the meeting discussed 'why we got into this position' and the way forward.

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update. While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed. The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses. It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for antibiotics for the treatment of Group A Strep. "Supplies of antibiotics for the treatment of Group A Strep have seen a surge in demand and may be temporarily in limited supply at certain wholesalers and pharmacies," said DHSC. "Supplies are available with manufacturers, and deliveries into wholesalers and pharmacies are being expedited and are expected in the coming days." If the formulation of antibiotic prescribed is unavailable, DHSC has asked clinicians and local pharmacy teams to consider prescribing an alternative form or strength of the antibiotic where appropriate, ensuring the patient is not intolerant to any of the excipients in the alternative and is counselled on the appropriate dose (and volume) required.